Inhalation Aerosols
-10%
portes grátis
Inhalation Aerosols
Physical and Biological Basis for Therapy, Third Edition
Hickey, Anthony J.; Mansour, Heidi M.
Taylor & Francis Ltd
03/2019
436
Dura
Inglês
9781138064799
15 a 20 dias
1454
Descrição não disponível.
PART I Fundamentals. 1. Physicochemical Properties of Respiratory Particles and Formulations. 2. Particle Deposition in the Respiratory Tract and the Effect of Respiratory Disease. 3. Mathematical Modeling of Inhaled Therapeutic Aerosol Deposition in the Respiratory Tract. 4. Lung Transporters and Absorption Mechanisms in the Lungs. 5. Bioavailability of Inhaled Compounds. 6. 3D Models as Tools for Inhaled Drug Development. 7. Overview of the Delivery Technologies for Inhalation Aerosols. PART II Applications, Influence of Lung Disease Pathophysiology on Aerosol Deposition, Inhaler Device Technique in Respiratory Disease, and Clinical Outcomes in Drug Performance Assessment. 8. Neonatal and Pediatric Inhalation Drug Delivery. 9. Asthma. 10. Drug Delivery in Pulmonary Aspergillosis. 11. Lung Cancer Inhalation Therapeutics. 12. Inhaled Therapeutics in Chronic Obstructive Pulmonary Disease. 13. Cystic Fibrosis Infection and Biofilm Busters. 14. Current and Future CFTR Therapeutics. 15. Innate and Adaptive Barrier Properties of Airway Mucus. 16. Nontuberculous Mycobacteria. 17. Inhalational Therapies for Non-Cystic Bronchiectasis. 18. Pulmonary Fibrosis. 19. Therapeutics in Pulmonary Hypertension. 20. Overview of Lung Surfactant and Respiratory Distress Syndrome. 21. Surfactant Aerosol Therapy for nRDS and ARDS. 22. Fundamentals in Nasal Drug Delivery. 23. Inhaled therapeutics against TB: The Promise of Pulmonary Treatment and Prevention Strategies in the Clinic. PART III Integrated Strategies (Reflecting Combined Elements from Chapters 8 through 23). 24. Inhaled Medication: Factors That Affect Lung Deposition. 25. A Critical Perspective on Future Developments Based on the Knowledge We Have Now. 26. Ensuring Effectiveness and Reproducibility of Inhaled Drug Treatment. 27. Conclusion.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Tobramycin Inhalation Solutions;Inhaled Tobramycin Powder;CFTR Modulator;NTM Lung Disease;F508del CFTR Mutation;Non-invasive Ventilation;NRF2 Activator;DPI Technology;Inhaled Corticosteroids;Aerosol Bolus;Mouth Throat Deposition;Dry Powder Inhaler;COPD Patient;Vibrating Mesh Nebulizers;Aerodynamic Particle Size Distribution;Jet Nebulizers;?m MMAD;Idiopathic Pulmonary Fibrosis;Particle Deposition;Cystic Fibrosis Transmembrane Conductance Regulator;CFTR Protein;non-CF Bronchiectasis;NTM Infection;IPF Treatment;MPPD Model
PART I Fundamentals. 1. Physicochemical Properties of Respiratory Particles and Formulations. 2. Particle Deposition in the Respiratory Tract and the Effect of Respiratory Disease. 3. Mathematical Modeling of Inhaled Therapeutic Aerosol Deposition in the Respiratory Tract. 4. Lung Transporters and Absorption Mechanisms in the Lungs. 5. Bioavailability of Inhaled Compounds. 6. 3D Models as Tools for Inhaled Drug Development. 7. Overview of the Delivery Technologies for Inhalation Aerosols. PART II Applications, Influence of Lung Disease Pathophysiology on Aerosol Deposition, Inhaler Device Technique in Respiratory Disease, and Clinical Outcomes in Drug Performance Assessment. 8. Neonatal and Pediatric Inhalation Drug Delivery. 9. Asthma. 10. Drug Delivery in Pulmonary Aspergillosis. 11. Lung Cancer Inhalation Therapeutics. 12. Inhaled Therapeutics in Chronic Obstructive Pulmonary Disease. 13. Cystic Fibrosis Infection and Biofilm Busters. 14. Current and Future CFTR Therapeutics. 15. Innate and Adaptive Barrier Properties of Airway Mucus. 16. Nontuberculous Mycobacteria. 17. Inhalational Therapies for Non-Cystic Bronchiectasis. 18. Pulmonary Fibrosis. 19. Therapeutics in Pulmonary Hypertension. 20. Overview of Lung Surfactant and Respiratory Distress Syndrome. 21. Surfactant Aerosol Therapy for nRDS and ARDS. 22. Fundamentals in Nasal Drug Delivery. 23. Inhaled therapeutics against TB: The Promise of Pulmonary Treatment and Prevention Strategies in the Clinic. PART III Integrated Strategies (Reflecting Combined Elements from Chapters 8 through 23). 24. Inhaled Medication: Factors That Affect Lung Deposition. 25. A Critical Perspective on Future Developments Based on the Knowledge We Have Now. 26. Ensuring Effectiveness and Reproducibility of Inhaled Drug Treatment. 27. Conclusion.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Tobramycin Inhalation Solutions;Inhaled Tobramycin Powder;CFTR Modulator;NTM Lung Disease;F508del CFTR Mutation;Non-invasive Ventilation;NRF2 Activator;DPI Technology;Inhaled Corticosteroids;Aerosol Bolus;Mouth Throat Deposition;Dry Powder Inhaler;COPD Patient;Vibrating Mesh Nebulizers;Aerodynamic Particle Size Distribution;Jet Nebulizers;?m MMAD;Idiopathic Pulmonary Fibrosis;Particle Deposition;Cystic Fibrosis Transmembrane Conductance Regulator;CFTR Protein;non-CF Bronchiectasis;NTM Infection;IPF Treatment;MPPD Model
